Download MendeleyStructure Based Design of 4-(3-Aminomethylphenyl) Piperidinyl-1-Amides: Novel, Potent, Selective, and Orally Bioavailable Inhibitors of Bii Tryptase
Levell, J., Astles, P., Eastwood, P., Cairns, J., Houille, O., Aldous, S., Merriman, G., Whitley, B., Pribish, J., Czekaj, M., Liang, G., Maignan, S., Guilloteau, J.-P., Dupuy, A., Davidson, J., Harrison, T., Morley, A., Watson, S., Fenton, G., Mccarthy, C., Romano, J., Mathew, R., Engers, D., Gardyan, M., Sides, K., Kwong, J., Tsay, J., Rebello, S., Shen, L., Wang, J., Luo, Y., Giardino, O., Lim, H.-K., Smith, K., Pauls, H.(2005) Bioorg Med Chem 13: 2859
- PubMed: 15781396
- DOI: https://doi.org/10.1016/j.bmc.2005.02.014
- Primary Citation of Related Structures:
2BM2 - PubMed Abstract:
Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase beta is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified beta-amidoester benzamidines as potent inhibitors of recombinant human betaII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.
Organizational Affiliation:
Drug Innovation and Approval, Aventis Pharmaceuticals, 1041 Route 202-206, Mail Stop N-103A, Bridgewater, NJ 08807-6800, USA. julian.levell@aventis.com
